Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Evariste Logo
Evariste Growth Score
58
CB Rank
77629
Heat Score
62
Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled platform, Frobenius.
Founded
obfuscation
PrivateSeed London, England, United Kingdom1-10 www.evariste.com/
Artificial Intelligence (AI)
Biotechnology
Health Care
Therapeutics
Overview

Evariste
Total Funding
obfuscation
Growth Score
58
Heat Score
62

Total Funding
obfuscation
obfuscation
Seed raised
obfuscation
Growth Score58
-5 pts
in past quarter
Heat Score 62
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Evariste

CB Rank
77629
Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled platform, Frobenius.
Founded
obfuscation
PrivateSeed London, England, United Kingdom1-10 www.evariste.com/
Artificial Intelligence (AI)
Biotechnology
Health Care
Therapeutics

Funding Rounds

Seed
OBF
in
obfuscation
Seed
OBF
in
obfuscation
Pre-Seed
OBF
in
obfuscation

Key People

Details

Legal Name Evariste Ltd
Operating Status Active
Company Type For Profit
Founders  Oliver Watson
About the Company

Evariste advances synthetic lethal oncology using its AI-enabled platform, Frobenius. The company uses its platform to identify novel synthetic lethal targets and biomarkers, and then addresses them by developing small molecule therapeutic drug candidates. Frobenius has been validated through several external partnerships and Evariste's own

internal pipeline, which includes a best-in-class PKMYT1 inhibitor program and several first-in-class assets aimed at novel targets

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Frobenius Platform
An AI-driven drug discovery platform for identifying synthetic lethal targets and designing small molecule therapeutics in oncology.
PKMYT1 Inhibitor (EVT-3023)
A small molecule therapeutic targeting PKMYT1 to induce synthetic lethality in cancers with high replication stress, supported by a novel biomarker.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed
obfuscation
Seed Round - Evariste Logo
Seed Round - Evariste
—
obfuscation
— Seed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 4 Contacts 6

Employee Profiles

News

News and Press

News•Dec 10, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

599
140.56%
 in past month

Active Website Tech Count

10Evariste is actively using 10 technologies for its website, according to BuiltWith. These include Common Crawl, Mobile Non Scaleable Content, and  reCAPTCHA.
Sub-Organizations
Frequently Asked Questions

Where is Evariste's headquarters? Evariste is located in London, England, United Kingdom.When was the last funding round for Evariste? Evariste closed its last funding round on
obfuscation
from a Seed round.Who are Evariste's competitors? Alternatives and possible competitors to Evariste may include Insilico Medicine, Nurix Therapeutics, and  Pairwise Plants.How much funding has Evariste raised to date? Evariste has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5d42803 1)
|